⌕
United Therapeutics · UTHR · Nasdaq
Tenet 72 · Solid
Compare
$584.10−0.64%At closeTenet 72 · Solid
$584.10−3.78 (−0.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

United Therapeutics (UTHR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is UTHR's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 17, 2026 · 14:03 ET
United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript…

UTHR −0.6% todayRead at source ↗
● MarketBeatNov 16, 2026 · 22:12 ET
United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter

United Therapeutics NASDAQ: UTHR is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a pipeline of regulatory …

UTHR −0.6% todayRead at source ↗
● Zacks Investment ResearchNov 16, 2026 · 12:40 ET
SGIOY or UTHR: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or United Therapeutics (UTHR).…

UTHR −0.6% todayRead at source ↗
● Seeking AlphaNov 16, 2026 · 07:52 ET
United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript

United Therapeutics Corporation (UTHR) Presents at UBS Global Biopharma Conference 2026 Transcript…

UTHR −0.6% todayRead at source ↗
● Defense WorldNov 16, 2026 · 04:01 ET
5,137 United Therapeutics Corporation $UTHR Shares Purchased by Fisher Asset Management LLC

Fisher Asset Management LLC grew its position in United Therapeutics Corporation (NASDAQ: UTHR) by 15.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange C…

UTHR −0.6% todayRead at source ↗
● Business WireNov 9, 2026 · 07:00 ETCOMPANY'S OWN WORDS
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and …

UTHR −0.6% todayRead at source ↗
● MarketBeatNov 4, 2026 · 17:15 ET
What United Therapeutics (UTHR) Said on Its Q3 Earnings Call

United Therapeutics NASDAQ: UTHR reported record third-quarter 2026 revenue of $833 million, driven in part by record Tyvaso sales of $504 million, while pushing back a planned regulatory submission for its soft mist inh…

UTHR −0.6% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 13:44 ET
United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript

United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript…

UTHR −0.6% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 10:31 ET
United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street esti…

UTHR −0.6% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 08:36 ET
United Therapeutics (UTHR) Q3 Earnings Miss Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $5.85 per share. This compares to earnings of $7.16 per share a year ago.…

UTHR −0.6% todayRead at source ↗
● Business WireNov 4, 2026 · 07:00 ETCOMPANY'S OWN WORDS
United Therapeutics Announces Buydown of Ralinepag Royalty

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that it has entered into an amendment with Arena Pharmaceut…

UTHR −0.6% todayRead at source ↗
● Business WireNov 4, 2026 · 06:30 ETCOMPANY'S OWN WORDS
United Therapeutics Corporation Reports Third Quarter 2026 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, …

UTHR −0.6% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 12:41 ET
SGIOY vs. UTHR: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and United Therapeutics (UTHR).…

UTHR −0.6% todayRead at source ↗
● Zacks Investment ResearchOct 28, 2026 · 11:07 ET
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

UTHR −0.6% todayRead at source ↗
● Business WireOct 28, 2026 · 07:00 ETCOMPANY'S OWN WORDS
United Therapeutics Announces FDA Clearance to Proceed with Clinical Trial for Treprostinil-Iloprost SMI in Pulmonary Arterial Hypertension

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has grant…

UTHR −0.6% todayRead at source ↗
● Defense WorldOct 27, 2026 · 04:13 ET
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $582.76, for a t…

UTHR −0.6% todayRead at source ↗
● Business WireOct 22, 2026 · 07:00 ETCOMPANY'S OWN WORDS
United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization

SILVER SPRING, M.D. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors has authorized a ne…

UTHR −0.6% todayRead at source ↗
● Business WireOct 21, 2026 · 07:00 ETCOMPANY'S OWN WORDS
United Therapeutics Corporation to Report Third Quarter 2026 Financial Results Before Market Open on Wednesday, November 4, 2026

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2026 financial results in a press release that will…

UTHR −0.6% todayRead at source ↗
● Business WireOct 20, 2026 · 07:00 ETCOMPANY'S OWN WORDS
United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the opening of its third Designated Pathogen-Free (DPF) fa…

UTHR −0.6% todayRead at source ↗
● Defense WorldOct 20, 2026 · 04:45 ET
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the firm's stock in a transaction on Friday, October 16th. The shares were sold at an average price of $534.66, …

UTHR −0.6% todayRead at source ↗
● Business WireOct 19, 2026 · 07:00 ETCOMPANY'S OWN WORDS
United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has grant…

UTHR −0.6% todayRead at source ↗
● Defense WorldOct 18, 2026 · 04:09 ET
United Therapeutics (NASDAQ:UTHR) CEO Sells $5,129,905.00 in Stock

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of …

UTHR −0.6% todayRead at source ↗
● Defense WorldOct 18, 2026 · 04:09 ET
United Therapeutics (NASDAQ:UTHR) Stock: Insider Paul Mahon Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price o…

UTHR −0.6% todayRead at source ↗
● Business WireOct 13, 2026 · 07:00 ETCOMPANY'S OWN WORDS
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster presentations will be presen…

UTHR −0.6% todayRead at source ↗
● Business WireSep 30, 2026 · 19:09 ETCOMPANY'S OWN WORDS
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of …

UTHR −0.6% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA36−0.4%
INTC4−0.5%
LAW4−8.6%
ABR3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just UTHR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.